Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Altered plasma metabolite levels can be detected years before a glioma diagnosis
Umeå University, Faculty of Science and Technology, Department of Chemistry.ORCID iD: 0000-0001-9228-0625
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology. Biobank Reserach Unit.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.
Show others and affiliations
2023 (English)In: JCI Insight, ISSN 2379-3708, Vol. 8, no 19, article id e171225Article in journal (Refereed) Published
Abstract [en]

Genetic and metabolic changes in tissue and blood are reported to occur several years before glioma diagnosis. Since gliomas are currently detected late, a liquid biopsy for early detection could affect the quality of life and prognosis of patients. Here, we present a nested case-control study of 550 prediagnostic glioma cases and 550 healthy controls from the Northern Sweden Health and Disease study (NSHDS) and the European Prospective Investigation into Cancer and Nutrition (EPIC) study. We identified 93 significantly altered metabolites related to glioma development up to 8 years before diagnosis. Out of these metabolites, a panel of 20 selected metabolites showed strong disease correlation and a consistent progression pattern toward diagnosis in both the NSHDS and EPIC cohorts, and they separated future cases from controls independently of biological sex. The blood metabolite panel also successfully separated both lower-grade glioma and glioblastoma cases from controls, up to 8 years before diagnosis in patients within the NSHDS cohort and up to 2 years before diagnosis in EPIC. Pathway enrichment analysis detected metabolites related to the TCA cycle, Warburg effect, gluconeogenesis, and cysteine, pyruvate, and tyrosine metabolism as the most affected.

Place, publisher, year, edition, pages
American Society For Clinical Investigation, 2023. Vol. 8, no 19, article id e171225
Keywords [en]
Brain cancer, Metabolism, Oncology
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-215372DOI: 10.1172/jci.insight.171225ISI: 001085355700001PubMedID: 37651185Scopus ID: 2-s2.0-85173580693OAI: oai:DiVA.org:umu-215372DiVA, id: diva2:1808405
Funder
Swedish Research Council, 2017-00650Swedish Research Council, 2019-01566Swedish Cancer Society, CAN2018/390Swedish Cancer Society, 19 0370Cancerforskningsfonden i Norrland, AMP 21-1045Cancerforskningsfonden i Norrland, AMP22-1084Sjöberg Foundation, 2020-01-07-08Public Health Agency of Sweden , 2020-2022World Cancer Research Fund InternationalRegion SkåneRegion VästerbottenAvailable from: 2023-10-31 Created: 2023-10-31 Last updated: 2024-10-02Bibliographically approved
In thesis
1. Metabolic signatures in blood for early detection of glioma
Open this publication in new window or tab >>Metabolic signatures in blood for early detection of glioma
2024 (English)Doctoral thesis, comprehensive summary (Other academic)
Alternative title[sv]
Metaboliska signaturer i blod för tidig upptäckt av gliom
Abstract [en]

Glioma is the most common malignant primary brain tumor among adults and is often detected at a late stage of the disease. Treatment often include surgical resection of the tumor followed by combined radiochemotherapy. Yet, the prognosis given to glioma patients is often poor, with the median survival for the most common and aggressive glioma subtype glioblastoma being only 15 months. Due to limited treatment options and poor prognosis, an earlier detection of gliomas could potentially improve the outcome and quality of life for patients. Intriguingly, previous studies have shown that the glioma development may actually start several years before clinical diagnosis is given. In this thesis, a search for altered metabolite levels in blood related to glioma development was conducted, to find biomarkers that show potential to be targets in an early detection tool of glioma and to improve the understanding of the mechanism of the disease.

In Paper I, pre-diagnostic metabolite levels in blood were analyzed from glioma cases that had been collected several years before they were diagnosed together with matched controls. A panel of 20 metabolites were discovered that could predict glioma development up to 8 years before diagnosis in the discovery cohort and up to 2 years before diagnosis in the validation cohort. The altered metabolites showed indication of an altered energy metabolism and imbalanced redox homeostasis.

In Paper II, the altered metabolite levels within 8 years to glioma diagnosis related to an altered energy metabolism was replicated. Longitudinal blood metabolite analysis from years before diagnosis to the time of surgery revealed an altered amino acid metabolism. A set of metabolites with diagnostic potential at surgery and years before diagnosis was presented.

In Paper III, a discovery analysis was conducted on altered metabolite levels at the time of glioma surgery compared to years before diagnosis. A large set of metabolites was significantly altered at surgery, with several metabolic pathways altered including the amino acid metabolism. The pre-diagnostic 20-metabolite panel discovered in Paper I was revisited and their levels were analyzed at surgery, where 8 metabolites showed further significantly elevated levels at surgery as compared to years before, indicating early detection and diagnostic potential for those metabolites.

Place, publisher, year, edition, pages
Umeå: Umeå University, 2024. p. 67
Keywords
Glioma, glioblastoma, liquid biopsy, blood, metabolites, early detection, surgery, N-lactoyl-amino-acids, N-lactoyl-phenylalanine
National Category
Cancer and Oncology Analytical Chemistry Bioinformatics (Computational Biology)
Identifiers
urn:nbn:se:umu:diva-230465 (URN)9789180705011 (ISBN)9789180705028 (ISBN)
Public defence
2024-11-08, Stora hörsalen (KBE303), KBC-huset, Linnaeus väg 6, Umeå, 09:00 (English)
Opponent
Supervisors
Available from: 2024-10-11 Created: 2024-10-01 Last updated: 2024-10-02Bibliographically approved

Open Access in DiVA

fulltext(11674 kB)83 downloads
File information
File name FULLTEXT01.pdfFile size 11674 kBChecksum SHA-512
8a914ea28493f83219f930799f75b2c01248d774ca6b083a2f67128cfa5d23b1c0bab71ec1675a9eacb2d0ec2a4f80131d476dabe10f884913dc709e85639e21
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Löding, SebastianAndersson, UlrikaNyberg, LarsAntti, HenrikBjörkblom, BennyMelin, Beatrice S.

Search in DiVA

By author/editor
Löding, SebastianAndersson, UlrikaNyberg, LarsAntti, HenrikBjörkblom, BennyMelin, Beatrice S.
By organisation
Department of ChemistryOncologyDepartment of Integrative Medical Biology (IMB)Diagnostic Radiology
In the same journal
JCI Insight
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 83 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 398 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf